Today, Karyopharm Therapeutics’ (KPTI) “Outperform” Rating Reaffirm at Wedbush

Today, Karyopharm Therapeutics’ (KPTI) “Outperform” Rating Reaffirm at Wedbush

Karyopharm Therapeutics Inc. (NASDAQ:KPTI)‘s stock had its “outperform” rating reaffirmed by research analysts at Wedbush in a research note issued on Tuesday. They currently have a $14.00 price target on the stock. Wedbush’s price objective would suggest a potential upside of 41.27% from the company’s previous close.

Several other analysts have also recently weighed in on the stock. Jefferies Group raised shares of Karyopharm Therapeutics from a “hold” rating to a “buy” rating and increased their price objective for the stock from $9.00 to $12.00 in a research report on Tuesday, August 30th. Robert W. Baird reaffirmed a “positive” rating and set a $16.00 price objective on shares of Karyopharm Therapeutics in a research report on Tuesday, September 6th. Vetr raised shares of Karyopharm Therapeutics from a “hold” rating to a “strong-buy” rating and set a $11.00 price objective for the company in a research report on Tuesday, September 6th. Zacks Investment Research raised shares of Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, July 21st. Finally, S&P Equity Research lowered their price objective on shares of Karyopharm Therapeutics from $9.06 to $7.55 in a research report on Tuesday, August 30th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. Karyopharm Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $15.47.

Shares of Karyopharm Therapeutics (NASDAQ:KPTI) traded down 1.00% during mid-day trading on Tuesday, reaching $9.91. The company’s stock had a trading volume of 56,629 shares. The firm’s 50 day moving average is $8.72 and its 200 day moving average is $8.34. The firm’s market cap is $408.72 million. Karyopharm Therapeutics has a one year low of $4.83 and a one year high of $19.38.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings results on Monday, November 7th. The company reported ($0.69) earnings per share for the quarter, topping the consensus estimate of ($0.81) by $0.12. On average, equities analysts anticipate that Karyopharm Therapeutics will post ($3.00) earnings per share for the current fiscal year.

In other Karyopharm Therapeutics news, insider Ran Frenkel sold 3,309 shares of the firm’s stock in a transaction on Monday, November 14th. The shares were sold at an average price of $10.06, for a total transaction of $33,288.54. Following the transaction, the insider now directly owns 14,691 shares of the company’s stock, valued at approximately $147,791.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 14.79% of the company’s stock.

Hedge funds have recently modified their holdings of the stock. Wellington Management Group LLP increased its stake in shares of Karyopharm Therapeutics by 631.9% in the first quarter. Wellington Management Group LLP now owns 1,269,485 shares of the company’s stock valued at $11,323,000 after buying an additional 1,096,029 shares during the last quarter. JPMorgan Chase & Co. increased its stake in Karyopharm Therapeutics by 29.0% in the first quarter. JPMorgan Chase & Co. now owns 280,206 shares of the company’s stock worth $2,500,000 after buying an additional 62,969 shares in the last quarter. Bank of New York Mellon Corp increased its stake in Karyopharm Therapeutics by 4.3% in the second quarter. Bank of New York Mellon Corp now owns 101,558 shares of the company’s stock worth $682,000 after buying an additional 4,173 shares in the last quarter. Swiss National Bank increased its stake in Karyopharm Therapeutics by 7.3% in the second quarter. Swiss National Bank now owns 36,850 shares of the company’s stock worth $247,000 after buying an additional 2,500 shares in the last quarter. Finally, New Leaf Venture Partners L.L.C. increased its stake in Karyopharm Therapeutics by 1,723.5% in the second quarter. New Leaf Venture Partners L.L.C. now owns 222,947 shares of the company’s stock worth $1,496,000 after buying an additional 210,721 shares in the last quarter. 49.20% of the stock is currently owned by institutional investors and hedge funds.

About Karyopharm Therapeutics

Related posts

Leave a Comment